Plain-English translation of NCT06174116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing (a medication called Caplyta) as an add-on treatment for people with schizophrenia who are already taking clozapine. Researchers want to see if this medication can improve cholesterol and fat levels in the blood, help with body weight and muscle, and reduce sleep problems. The study lasts 12 weeks, and half of participants will receive the medication while the other half receive a placebo (inactive pill).
Clozapine is an effective antipsychotic, but it can cause weight gain and unhealthy changes in cholesterol and fat levels. This medication might help reduce those side effects while also helping people sleep better, which could improve overall health and quality of life.
You likely qualify if…
You likely don't qualify if…
You would take either the new medication or a placebo (a pill that looks the same but has no active ingredient) twice daily for 12 weeks. During that time, you'll have regular visits where researchers check your psychiatric symptoms, mood, sleep, body composition, and blood work to measure cholesterol and fat levels. The study measures various health and wellness outcomes to see how the treatment affects your overall well-being.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States